On Friday, Hawaiian Holdings, Inc. (NASDAQ:HA)’s shares inclined 1.20% to $23.68.
Hawaiian Airlines, Inc., a partner of Hawaiian Holdings, Inc. (HA), has declared its system-wide traffic statistics for the month of May and year to date.
Hawaiian® has led all U.S. carriers in on-time performance for each of the past 11 years (2004-2014) as stated by the U.S. Department of Transportation. Consumer surveys by Condé Nast Traveler, Travel + Leisure and Zagat have all ranked Hawaiian the highest of all domestic airlines serving Hawai’i.
Hawaiian Holdings, Inc., through its partner, Hawaiian Airlines, Inc., engages in the planned air transportation of passengers and cargo. It offers daily services on North America routes between the state of Hawaii and Los Angeles, Oakland, Sacramento, San Diego, San Francisco, and San Jose, California; Las Vegas, Nevada; Phoenix, Arizona; Portland, Oregon; and Seattle, Washington, in addition to daily services on its neighbor island routes among the four major islands of the state of Hawaii.
Nucor Corporation (NYSE:NUE)’s shares dropped -0.29% to $48.92.
The board of directors of Nucor Corporation (NUE) declared the regular quarterly cash dividend of $0.3725 per share on Nucor’s common stock. This cash dividend is payable on August 11, 2015 to stockholders of record on June 30, 2015, and is Nucor’s 169th successive quarterly cash dividend.
Nucor and associates are manufacturers of steel products, with operating facilities primarily in the U.S. and Canada. Products produced comprise: carbon and alloy steel — in bars, beams, sheet and plate; steel piling; steel joists and joist girders; steel deck; fabricated concrete reinforcing steel; cold finished steel; steel fasteners; metal building systems; steel grating and expanded metal; and wire and wire mesh. Nucor, through The David J. Joseph Company, also brokers ferrous and nonferrous metals, pig iron and HBI/DRI; supplies ferro-alloys; and processes ferrous and nonferrous scrap. Nucor is North America’s largest recycler.
Nucor Corporation manufactures and sells steel and steel products in the United States and internationally. It operates through three segments: Steel Mills, Steel Products, and Raw Materials.
At the end of Friday’s trade, Molson Coors Brewing Company (NYSE:TAP)‘s shares declined -3.01% to $72.61.
Molson Coors Brewing Company (TAP) eclared that consumer product executive Mary Lynn Ferguson-McHugh will join its board of directors, effective right away.
Ferguson-McHugh is the Group President of Global Family Care for Procter & Gamble Company (PG), one of the world’s largest makers of consumer packaged goods. P&G has one of the strongest portfolios of trusted, quality, leadership brands, counting Always, Bounty, Charmin, Crest, Gillette, Olay, Oral-B, Pampers, Pantene and Tide.
Molson Coors Brewing Company manufactures and sells beer and other beverage products. The company sells its products under the Coors Light, Molson Canadian, Carling, Carling Black Label, Coors Altitude, Coors Banquet, Creemore Springs, the Granville Island, Keystone Light, Mad Jack, Molson Canadian 67, Molson Canadian Cider, Molson Dry, Molson Export, Pilsner, and the Rickard’s family brands in Canada; and brews or distributes under the Amstel Light, Heineken, Murphy’s, Newcastle Brown Ale, Strongbow cider, Desperados, Dos Equis, Moretti, Sol, Tecate, Miller Chill, and Miller Genuine Draft brands.
Sorrento Therapeutics Inc (NASDAQ:SRNE), ended its Friday’s trading session with 12.85% gain, and closed at $15.72.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has reached a non-exclusive research and clinical trial partnershipagreement with Sorrento Therapeutics, Inc. (SRNE) to evaluate combinations of Advaxis’s Lm-LLO cancer immunotherapy technology platform, counting ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento’s fully human antibodies targeting immune checkpoints, counting GITR, OX40, LAG-3 and TIM-3. Sorrento has one of the largest and most diverse fully human antibody libraries in the industry designed to facilitate rapid identification and selection of highly specific therapeutic monoclonal antibody (mAb) product candidates.
Advaxis’s preclinical program for ADXS-HPV formerly examined its therapeutic potential in combination with agonistic research antibodies, counting anti-OX40 and anti-GITR. Preclinical data demonstrated that the combination of ADXS-HPV with agonistic research antibodies led to noteworthy inhibition of tumor growth and prolonged survival in tumor-bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively (AACR Abstract #LB-229).
Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, counting the treatment of chronic cancer pain, in addition to developing therapeutic products for other indications, such as immunology and infectious diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
